© 2022 BioMarin. All rights reserved.

Investors & Media
NASDAQ: BMRN
Loading...
Stock Quote
NASDAQBMRN
Latest Events

13th Annual Jefferies Global Healthcare Conference 2022
Listen to the Replay

 

Credit Suisse 31st Annual Healthcare Conference 2022
Listen to the Replay

All Events

Press Releases
Nov 23, 2022

FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing...

All Press Releases

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.

 

Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

 

Learn More

Contact Us

Investor Relations
415-455-7558
IR@BMRN.com

Media & Press
415-455-7451
corporatecommunications2@BMRN.com

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more! 


Subscribe